Copyright Reports & Markets. All rights reserved.

Global Autologous iPSC-Derived Cell Therapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Autologous iPSC-Derived Cell Therapy by Type
    • 1.3.1 Overview: Global Autologous iPSC-Derived Cell Therapy Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Autologous iPSC-Derived Cell Therapy Consumption Value Market Share by Type in 2025
    • 1.3.3 Autologous iPSC-Derived Neural Cell Therapy
    • 1.3.4 Autologous iPSC-Derived Retinal Cell Therapy
    • 1.3.5 Autologous iPSC-Derived Cardiovascular Cell Therapy
    • 1.3.6 Autologous iPSC-Derived Islet Cell Therapy
    • 1.3.7 Autologous iPSC-Derived Mesenchymal-Like Cell Therapy
    • 1.3.8 Autologous iPSC-Derived Immune Cell Therapy
    • 1.3.9 Other Autologous iPSC-Derived Cell Therapy
  • 1.4 Classification of Autologous iPSC-Derived Cell Therapy by Somatic Cell Source
    • 1.4.1 Overview: Global Autologous iPSC-Derived Cell Therapy Market Size by Somatic Cell Source: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Autologous iPSC-Derived Cell Therapy Consumption Value Market Share by Somatic Cell Source in 2025
    • 1.4.3 Peripheral Blood-Derived
    • 1.4.4 Skin Fibroblast-Derived
    • 1.4.5 Urine Cell-Derived
    • 1.4.6 Dental Pulp Cell-Derived
    • 1.4.7 Other Somatic Cell-Derived
  • 1.5 Classification of Autologous iPSC-Derived Cell Therapy by Delivery Form
    • 1.5.1 Overview: Global Autologous iPSC-Derived Cell Therapy Market Size by Delivery Form: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global Autologous iPSC-Derived Cell Therapy Consumption Value Market Share by Delivery Form in 2025
    • 1.5.3 Cell Suspension for Injection
    • 1.5.4 Cell Sheet
    • 1.5.5 Scaffold-Seeded Cell Patch
    • 1.5.6 Encapsulated Cell Implant
    • 1.5.7 Tissue Aggregate or Organoid Graft
    • 1.5.8 Other Delivery Form
  • 1.6 Classification of Autologous iPSC-Derived Cell Therapy by Development Stage
    • 1.6.1 Overview: Global Autologous iPSC-Derived Cell Therapy Market Size by Development Stage: 2021 Versus 2025 Versus 2032
    • 1.6.2 Global Autologous iPSC-Derived Cell Therapy Consumption Value Market Share by Development Stage in 2025
    • 1.6.3 Preclinical Candidate
    • 1.6.4 IND-Enabling Candidate
    • 1.6.5 Phase I Clinical Product
    • 1.6.6 Phase II Clinical Product
    • 1.6.7 Pivotal or Registration Stage Product
    • 1.6.8 Approved Product
  • 1.7 Global Autologous iPSC-Derived Cell Therapy Market by Application
    • 1.7.1 Overview: Global Autologous iPSC-Derived Cell Therapy Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.7.2 Neurodegenerative Diseases
    • 1.7.3 Retinal Degenerative Diseases
    • 1.7.4 Cardiovascular Ischemic Diseases
    • 1.7.5 Metabolic and Endocrine Diseases
    • 1.7.6 Immune and Inflammatory Diseases
    • 1.7.7 Other Regenerative Applications
  • 1.8 Global Autologous iPSC-Derived Cell Therapy Market Size & Forecast
  • 1.9 Global Autologous iPSC-Derived Cell Therapy Market Size and Forecast by Region
    • 1.9.1 Global Autologous iPSC-Derived Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
    • 1.9.2 Global Autologous iPSC-Derived Cell Therapy Market Size by Region, (2021-2032)
    • 1.9.3 North America Autologous iPSC-Derived Cell Therapy Market Size and Prospect (2021-2032)
    • 1.9.4 Europe Autologous iPSC-Derived Cell Therapy Market Size and Prospect (2021-2032)
    • 1.9.5 Asia-Pacific Autologous iPSC-Derived Cell Therapy Market Size and Prospect (2021-2032)
    • 1.9.6 South America Autologous iPSC-Derived Cell Therapy Market Size and Prospect (2021-2032)
    • 1.9.7 Middle East & Africa Autologous iPSC-Derived Cell Therapy Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Aspen Neuroscience
    • 2.1.1 Aspen Neuroscience Details
    • 2.1.2 Aspen Neuroscience Major Business
    • 2.1.3 Aspen Neuroscience Autologous iPSC-Derived Cell Therapy Product and Solutions
    • 2.1.4 Aspen Neuroscience Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Aspen Neuroscience Recent Developments and Future Plans
  • 2.2 UniXell Biotechnology
    • 2.2.1 UniXell Biotechnology Details
    • 2.2.2 UniXell Biotechnology Major Business
    • 2.2.3 UniXell Biotechnology Autologous iPSC-Derived Cell Therapy Product and Solutions
    • 2.2.4 UniXell Biotechnology Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 UniXell Biotechnology Recent Developments and Future Plans
  • 2.3 Oryon Cell Therapies
    • 2.3.1 Oryon Cell Therapies Details
    • 2.3.2 Oryon Cell Therapies Major Business
    • 2.3.3 Oryon Cell Therapies Autologous iPSC-Derived Cell Therapy Product and Solutions
    • 2.3.4 Oryon Cell Therapies Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Oryon Cell Therapies Recent Developments and Future Plans
  • 2.4 Cellio Therapeutics
    • 2.4.1 Cellio Therapeutics Details
    • 2.4.2 Cellio Therapeutics Major Business
    • 2.4.3 Cellio Therapeutics Autologous iPSC-Derived Cell Therapy Product and Solutions
    • 2.4.4 Cellio Therapeutics Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Cellio Therapeutics Recent Developments and Future Plans
  • 2.5 Cellino
    • 2.5.1 Cellino Details
    • 2.5.2 Cellino Major Business
    • 2.5.3 Cellino Autologous iPSC-Derived Cell Therapy Product and Solutions
    • 2.5.4 Cellino Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Cellino Recent Developments and Future Plans
  • 2.6 Kadis Bio
    • 2.6.1 Kadis Bio Details
    • 2.6.2 Kadis Bio Major Business
    • 2.6.3 Kadis Bio Autologous iPSC-Derived Cell Therapy Product and Solutions
    • 2.6.4 Kadis Bio Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Kadis Bio Recent Developments and Future Plans
  • 2.7 HeartWorks
    • 2.7.1 HeartWorks Details
    • 2.7.2 HeartWorks Major Business
    • 2.7.3 HeartWorks Autologous iPSC-Derived Cell Therapy Product and Solutions
    • 2.7.4 HeartWorks Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 HeartWorks Recent Developments and Future Plans
  • 2.8 iCamuno Biotherapeutics
    • 2.8.1 iCamuno Biotherapeutics Details
    • 2.8.2 iCamuno Biotherapeutics Major Business
    • 2.8.3 iCamuno Biotherapeutics Autologous iPSC-Derived Cell Therapy Product and Solutions
    • 2.8.4 iCamuno Biotherapeutics Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 iCamuno Biotherapeutics Recent Developments and Future Plans
  • 2.9 Shize Biomedicine
    • 2.9.1 Shize Biomedicine Details
    • 2.9.2 Shize Biomedicine Major Business
    • 2.9.3 Shize Biomedicine Autologous iPSC-Derived Cell Therapy Product and Solutions
    • 2.9.4 Shize Biomedicine Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Shize Biomedicine Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Autologous iPSC-Derived Cell Therapy Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Autologous iPSC-Derived Cell Therapy by Company Revenue
    • 3.2.2 Top 3 Autologous iPSC-Derived Cell Therapy Players Market Share in 2025
    • 3.2.3 Top 6 Autologous iPSC-Derived Cell Therapy Players Market Share in 2025
  • 3.3 Autologous iPSC-Derived Cell Therapy Market: Overall Company Footprint Analysis
    • 3.3.1 Autologous iPSC-Derived Cell Therapy Market: Region Footprint
    • 3.3.2 Autologous iPSC-Derived Cell Therapy Market: Company Product Type Footprint
    • 3.3.3 Autologous iPSC-Derived Cell Therapy Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Autologous iPSC-Derived Cell Therapy Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Autologous iPSC-Derived Cell Therapy Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Autologous iPSC-Derived Cell Therapy Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Autologous iPSC-Derived Cell Therapy Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Autologous iPSC-Derived Cell Therapy Consumption Value by Type (2021-2032)
  • 6.2 North America Autologous iPSC-Derived Cell Therapy Market Size by Application (2021-2032)
  • 6.3 North America Autologous iPSC-Derived Cell Therapy Market Size by Country
    • 6.3.1 North America Autologous iPSC-Derived Cell Therapy Consumption Value by Country (2021-2032)
    • 6.3.2 United States Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Autologous iPSC-Derived Cell Therapy Consumption Value by Type (2021-2032)
  • 7.2 Europe Autologous iPSC-Derived Cell Therapy Consumption Value by Application (2021-2032)
  • 7.3 Europe Autologous iPSC-Derived Cell Therapy Market Size by Country
    • 7.3.1 Europe Autologous iPSC-Derived Cell Therapy Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
    • 7.3.3 France Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Autologous iPSC-Derived Cell Therapy Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Autologous iPSC-Derived Cell Therapy Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Autologous iPSC-Derived Cell Therapy Market Size by Region
    • 8.3.1 Asia-Pacific Autologous iPSC-Derived Cell Therapy Consumption Value by Region (2021-2032)
    • 8.3.2 China Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
    • 8.3.5 India Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Autologous iPSC-Derived Cell Therapy Consumption Value by Type (2021-2032)
  • 9.2 South America Autologous iPSC-Derived Cell Therapy Consumption Value by Application (2021-2032)
  • 9.3 South America Autologous iPSC-Derived Cell Therapy Market Size by Country
    • 9.3.1 South America Autologous iPSC-Derived Cell Therapy Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Autologous iPSC-Derived Cell Therapy Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Autologous iPSC-Derived Cell Therapy Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Autologous iPSC-Derived Cell Therapy Market Size by Country
    • 10.3.1 Middle East & Africa Autologous iPSC-Derived Cell Therapy Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Autologous iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Autologous iPSC-Derived Cell Therapy Market Drivers
  • 11.2 Autologous iPSC-Derived Cell Therapy Market Restraints
  • 11.3 Autologous iPSC-Derived Cell Therapy Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Autologous iPSC-Derived Cell Therapy Industry Chain
  • 12.2 Autologous iPSC-Derived Cell Therapy Upstream Analysis
  • 12.3 Autologous iPSC-Derived Cell Therapy Midstream Analysis
  • 12.4 Autologous iPSC-Derived Cell Therapy Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Autologous iPSC-Derived Cell Therapy market size was valued at US$ 46.30 million in 2025 and is forecast to a readjusted size of US$ 337 million by 2032 with a CAGR of 31.2% during review period.
    Autologous iPSC-Derived Cell Therapies are personalized regenerative medicine products manufactured by reprogramming a patient's own somatic cells, such as peripheral blood cells or skin fibroblasts, into induced pluripotent stem cells (iPSCs), followed by directed differentiation into functional cell types including dopaminergic neural progenitor cells, retinal pigment epithelial (RPE) cells, cardiovascular cells, islet-like cells, or immune cells. These differentiated cells are subsequently transplanted or infused back into the same patient. This therapeutic approach emphasizes immune compatibility, high cell purity, genomic stability, minimal tumorigenic risk, GMP-compliant closed manufacturing processes, and complete product traceability. It is primarily being developed for neurodegenerative diseases, retinal degenerative disorders, ischemic cardiovascular diseases, metabolic and endocrine disorders, and tissue regeneration applications. The overall gross margin is approximately 52%.
    Demand for autologous iPSC-derived cell therapies is primarily driven by the significant unmet medical needs in degenerative diseases where conventional drug therapies can only alleviate symptoms rather than restore lost tissue function. Diseases such as Parkinson's disease, retinal degeneration, myocardial injury, and pancreatic islet dysfunction all have well-established rationales for cell replacement therapy. Because autologous cells are immunologically matched to the patient, this approach can substantially reduce the risk of immune rejection and minimize the need for long-term immunosuppressive therapy, making it particularly attractive for applications requiring durable cell survival and functional integration.
    The key challenge for industrial development is transforming patient-specific cell manufacturing from laboratory-scale processes into standardized, reproducible, and GMP-compliant commercial production. Companies are building integrated platforms covering peripheral blood or skin sample collection, iPSC line establishment, directed differentiation, residual undifferentiated cell elimination, genomic stability testing, and closed, automated manufacturing systems. Future competitiveness will depend not only on clinical outcomes in individual indications but also on manufacturing turnaround time, production success rate, quality control standards, and optimized cell delivery procedures.
    Regionally, the United States, China, Japan, and South Korea are leading the development of autologous iPSC-derived therapies. Ongoing clinical studies and regulatory engagement are expected to continue driving demand for early-stage manufacturing services, CDMO partnerships, and automated cell production equipment. Despite challenges including high manufacturing costs, lengthy production timelines, patient-to-patient variability, and stringent long-term follow-up requirements, successful demonstration of safety and functional efficacy in key indications could enable autologous iPSC platforms to expand from a limited number of high-value indications into a broad range of personalized regenerative medicine products.
    Report Scope
    This report is a detailed and comprehensive analysis for global Autologous iPSC-Derived Cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Autologous iPSC-Derived Cell Therapy market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Autologous iPSC-Derived Cell Therapy market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Autologous iPSC-Derived Cell Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Autologous iPSC-Derived Cell Therapy market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Autologous iPSC-Derived Cell Therapy
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Autologous iPSC-Derived Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Aspen Neuroscience, UniXell Biotechnology, Oryon Cell Therapies, Cellio Therapeutics, Cellino, Kadis Bio, HeartWorks, iCamuno Biotherapeutics, Shize Biomedicine, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Autologous iPSC-Derived Cell Therapy market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Autologous iPSC-Derived Neural Cell Therapy
    Autologous iPSC-Derived Retinal Cell Therapy
    Autologous iPSC-Derived Cardiovascular Cell Therapy
    Autologous iPSC-Derived Islet Cell Therapy
    Autologous iPSC-Derived Mesenchymal-Like Cell Therapy
    Autologous iPSC-Derived Immune Cell Therapy
    Other Autologous iPSC-Derived Cell Therapy
    Market segment by Somatic Cell Source
    Peripheral Blood-Derived
    Skin Fibroblast-Derived
    Urine Cell-Derived
    Dental Pulp Cell-Derived
    Other Somatic Cell-Derived
    Market segment by Delivery Form
    Cell Suspension for Injection
    Cell Sheet
    Scaffold-Seeded Cell Patch
    Encapsulated Cell Implant
    Tissue Aggregate or Organoid Graft
    Other Delivery Form
    Market segment by Development Stage
    Preclinical Candidate
    IND-Enabling Candidate
    Phase I Clinical Product
    Phase II Clinical Product
    Pivotal or Registration Stage Product
    Approved Product
    Market segment by Application
    Neurodegenerative Diseases
    Retinal Degenerative Diseases
    Cardiovascular Ischemic Diseases
    Metabolic and Endocrine Diseases
    Immune and Inflammatory Diseases
    Other Regenerative Applications
    Market segment by players, this report covers
    Aspen Neuroscience
    UniXell Biotechnology
    Oryon Cell Therapies
    Cellio Therapeutics
    Cellino
    Kadis Bio
    HeartWorks
    iCamuno Biotherapeutics
    Shize Biomedicine
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    Chapter Outline
    Chapter 1, to describe Autologous iPSC-Derived Cell Therapy product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Autologous iPSC-Derived Cell Therapy, with revenue, gross margin, and global market share of Autologous iPSC-Derived Cell Therapy from 2021 to 2026.
    Chapter 3, the Autologous iPSC-Derived Cell Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Autologous iPSC-Derived Cell Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Autologous iPSC-Derived Cell Therapy.
    Chapter 13, to describe Autologous iPSC-Derived Cell Therapy research findings and conclusion.

    Buy now